





Oral Potentially Malignant Disorders Day (OPMDay)

Faculty of Medicine of the University of Porto (FMUP) Porto – Portugal, June 6th & 7th

Day 1 – 6 th June 2024 – INTERCEPTOR Day	
9:30 to 10:30	Registration and check-in
10:30 to 11:00	Welcome & objectives of the day
11:00 to 13:00	Working Group parallel meetings - Breakout-room session 1: Working Groups 1/6/7 - Breakout-room session 2: Working Groups 2/3 - Breakout-room session 3: Working Groups 4/5
13:00 to 14:00	Lunch break
14:00 to 16:00	Progress report on INTERCEPTOR WGs
16:00 to 16:30	Coffee break
16:30 to 18:30	Management Committee
19:30	Dinner





Day 2 – 7 th June 2024 – OPMDay		
08:30 to 09:00	Registration	
09:00 to 9:15	Welcome : Rui Amaral Mendes, Senada Koljenovic and Pierre Saintigny	
09:15 to 09:45	Keynote 1: Treating patients with OPMDs. Where are we now? - Giovanni Lodi (Università degli Studi di Milano)	
09:45 to 10:45	Theme 1: Biomarkers and biological mechanisms Moderators: Daniela Elena Costea/Izge Shanlitourk • Demystifying the molecular landscape of malignant transformation of Oral Potentially Malignant Disorders (OPMDs) using spatial transcriptomics Omar Kujan (University of Western Australia - Australia) • Harnessing the immune system to manage oral dysplasia Sook Bin-Woo (University of Harvard - US) • Artificial Intelligence-based Oral Cancer Diagnosis from mRNA Biomarkers: Multicohort Validation and Demographic Generalization Selected abstract - presenter Vaishnavi Balaji (UK) • Immune-based Stratification and Evolutionary Biomarkers In Oral potentially malignant disorders (ISEBIO) Selected abstract - presenter Marine Benaïssa (France)	
10:45 to 11:00	Coffee break and Poster view	
11:00 to 12:00	Theme 2: Clinical & Pathological diagnosis Moderators: Paolo Bossi/Bojan Poposki • Adjunctive Tools in Early Diagnosis of Oral Cancer - Past, Present and Future Miguel Gonzáles-Moles (University of Granada - Spain)	





	 Histopathological Challenges in the Diagnosis of OPMD and Oral Cancer Senada Koljenovic (University of Antwerp - Belgium) Early detection of OPMD and OSCC using mutation analysis of DNA in saliva and plasma Selected abstract - presenter Sonia Del Marro (Spain) Raman spectroscopy for identification and monitoring of oral potentially malignant disorders Selected abstract - presenter Fiona Lyng (Ireland)
12:00 to 13:00	Introduction to set the stage for the round table: Patient's representatives; ethics and health-economics
13:00 to 14: 00	Lunch break
14:00 to 14:30	Keynote 2: Controversies in Oral Potentially Malignant Disorders – Prof. WM Tilakaratne (University of Malaya – Malaysia)
14:30 to 15:30	 Theme 3: Disease management Moderators: Antonella Cardone/ Sonia del Marro Risk factors and Life style's impact in Oral Carcinogenesis





	 Intralesional immunotherapy for the prevention of malignant transformation in high-risk oral potentially malignant disorders Selected abstract - presenter Luigi Lorini (Italy)
15:30 to 16:00	Coffee break and Poster view
16:00 to 16:15	Award Ceremony
16:15 to 17:15	Theme 4: Clinico-pathological session Moderators: Rui Amaral Mendes/Tamás Dániel Csűry
17:15 – 17:30	Closing remarks





Scientific Board (Core group)

Rui Amaral Mendes	Professor, Faculty of Medicine, University of Porto - MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences Researcher at CINTESIS@RISE, Faculty of Medicine, University of Porto (Clinical and Translational Research in Oncology) Adjunct Professor of Oral and Maxillofacial Medicine, Department of Oral and Maxillofacial Medicine and Diagnostic Sciences, Case Western Reserve University, Cleveland, OH, USA
Paolo Bossi	Humanitas University and Humanitas Cancer center, Italy
Marine Benaissa	Science Communication Coordinator & INTERCEPTOR Project Manager, Department of Translational Medecine, Centre Léon Bérard, Lyon 69008, France
Antonella Cardone	CEO of Cancer Patients Europe, the pan-European and all-cancer types patient association, Belgium
Daniela Elena Costea	Professor, Gade Laboratory for Pathology, Department of Clinical Medicine and Centre for Cancer Biomarkers CCBio, Haukeland University Hospital, University of Bergen, Norway
Moshe Elkabets	Associate Professor at Ben-Gurion University. Research focus on development & therapy of head and neck cancer. Drug resistance, tumor microenvironment and immunity, Israel.
Haly Holmes	Periodontist at University of the Western Cape. University of the Western Cape. City of Cape Town, Western Cape, South Africa
Keith Hunter	Professor of Head and Neck Pathology, Liverpool Head and Neck Centre, Molecular and Clinical Cancer Medicine, University of Liverpool, United-Kingdom
Senada Koljenović	Professor and Head of Department of Pathology, Antwerp University Hospital/ University of Antwerp, Belgium





Zisis Kozlakidis	Head of the Laboratory Services and Biobank Group (LSB) at IARC, WHO.
Carina Ladeira	Adjunct Professor, Higher School of Health Technologies of Lisbon – Polytechnic Institute of Lisbon. Diagnosis Sciences and Therapeutics and Public Health Department Researcher in H&TRC- Health & Technology Research Center and NOVA National School Public Health Research Centre.
Valesca Retèl	Head Health Technology Assessment (HTA) department, Netherlands Cancer Institute, Professor translational HTA Erasmus University Rotterdam, The Netherlands
Pierre Saintigny	Department of Medical Oncology, Centre Léon Bérard, Lyon, France ; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France.
Dipak Sapkota	Professor, Department of Oral Biology, Faculty of Dentistry, University of Oslo, Norway Academic editor of The Norwegian Dental Journal
Merva Soluk Tekkeşin	Grant Awarding Coordinator of the COST Action INTERCEPTOR and Professor of Oral Pathology - Department of Tumour Pathology - Institute of Oncology, Istanbul University - 34093 Capa- Istanbul, Turkey